Related references
Note: Only part of the references are listed.Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
Ziming Li et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
Liang Zeng et al.
ONCOTARGETS AND THERAPY (2018)
Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients
Oscar Juan et al.
LUNG CANCER (2017)
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement
Jieyu Wu et al.
BMC CANCER (2016)
Efficacy of of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
Yen-Fu Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
Dickran Kazandjian et al.
ONCOLOGIST (2016)
Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy
Zhengbo Song et al.
CANCER MEDICINE (2016)
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer
Ying Liang et al.
CLINICAL LUNG CANCER (2015)
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
Giulio Metro et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
Matthias Scheffler et al.
ONCOTARGET (2015)
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
S. -H. I. Ou et al.
ANNALS OF ONCOLOGY (2014)
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations
Yen-Fu Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
H. R. Kim et al.
ANNALS OF ONCOLOGY (2013)
A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements
Jonathan W. Riess et al.
CLINICAL LUNG CANCER (2013)
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement-Positive Non-Small-Cell Lung Cancer
Hiroyasu Kaneda et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Justin F. Gainor et al.
ONCOLOGIST (2013)
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Share Paper
